| Nov 19 |
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap
|
| Nov 18 |
Aldeyra announces FDA acceptance of resubmitted reproxalap application
|
| Nov 18 |
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement
|
| Nov 14 |
Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference
|
| Nov 14 |
Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects
|
| Sep 5 |
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
|
| Sep 4 |
High Growth Tech Stocks To Watch In The United States
|
| Aug 30 |
Aldeyra Therapeutics Inc (NASDAQ:ALDX) A Bull Case Theory
|
| Aug 28 |
Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership
|
| Aug 9 |
Aldeyra’s Phase III clinical trial of Reproxalap meets primary endpoint
|
